Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie HCV Revenue Surprises Again, But Falloff Is Coming

Executive Summary

Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.

Advertisement

Related Content

AbbVie Hit Harder By EU Humira Biosimilars Than Projected
AbbVie Hit Harder By EU Humira Biosimilars Than Projected
Q3 Pharma Earnings Preview: AbbVie, Lilly, AstraZeneca And Bayer
Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie
Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie
As Gilead Seeks New CEO, Second Quarter Shows Stability
AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access
HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last
AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV
Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel